This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lockhart, A. C. Articles by Rothenberg, M. L. Search for Related Content PubMed PubMed Citation Articles by Lockhart, A. C. Articles by Rothenberg, M. L.

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

¹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; ² Pharmacia Corp., Peapack, New Jersey; and ³ Pharmacia Corp., Milan, Italy

Purpose: This study was performed to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetics of brostallicin, a nonalkylating DNA minor groove binder and a synthetic derivative of distamycin A, given as a weekly i.v. infusion.

Experimental Design: Using an accelerated dose escalation design, patients with advanced solid tumor malignancies were treated with brostallicin administered as a 10-min i.v. infusion on days 1, 8, and 15 of a 28-day cycle. The starting dose of brostallicin was 0.3 mg/m²/week. To study the pharmacokinetic behavior of brostallicin, serial blood samples were obtained before and after the first and last infusions during cycle 1, and in cycles 2 and 4 in a limited number of patients.

Results: Fourteen patients received 32 complete cycles of brostallicin. Dose-limiting toxicity was febrile neutropenia and was observed in 3 of 5 patients treated at 4.8 mg/m²/week. The maximum tolerated dose and recommended Phase II dose was 2.4 mg/m²/week. The mean ± SD terminal half-life at the maximum tolerated dose was 4.6 ± 4.1 h. There was moderate distribution of brostallicin into tissues, and the clearance was 20% of the hepatic blood flow. The area under the concentration time curve_0- of brostallicin increased in a dose-linear fashion. No significant relationship was observed between any plasma pharmacokinetic parameter and clinical toxicities. There were no objective responses during the trial, but 5 patients had stable disease after two cycles of treatment.

Conclusions: The dose-limiting toxicity of weekly brostallicin was neutropenia. Systemic exposure increases linearly with dose. The recommended dose for Phase II studies is 2.4 mg/m² on days 1, 8, and 15 of a 28-day cycle.

This article has been cited by other articles:

				C. J. Chou, M. E. Farkas, S. M. Tsai, D. Alvarez, P. B. Dervan, and J. M. Gottesfeld Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia Mol. Cancer Ther., April 1, 2008; 7(4): 769 - 778. [Abstract] [Full Text] [PDF]

				J. H. Ostrander, A. R. Daniel, K. Lofgren, C. G. Kleer, and C. A. Lange Breast Tumor Kinase (Protein Tyrosine Kinase 6) Regulates Heregulin-Induced Activation of ERK5 and p38 MAP Kinases in Breast Cancer Cells Cancer Res., May 1, 2007; 67(9): 4199 - 4209. [Abstract] [Full Text] [PDF]